具体来看：2022年至2024年及2025年一季度，泰诺麦博营收分别为433.98万元、0万元、1505.59万元、16.93万元，净亏损分别为4.29亿元、4.46亿元、5.15亿 元、1.77亿元。 | 项目 | 2025.3.31/ | 2024.12.31/ | 2023.12.31/ | | --- | --- | --- | --- | | | 2025年1-3月 | 2024 年度 | 2023 年度 | | 资产总额(万元) | 113,326.63 | 93,329.82 | 99.193.23 | | 归属于母公司所有者权益(万 | 49,301.02 | 38,304.65 | 71.230.34 | | 元) | | | | | 资产负债率(母公司)(%) | 56.48 | 58.90 | 28.17 | | 营业收入(万元) | 16.93 | 1.505.59 | | | 净利润(万元) | -17.671.95 | -51,476.83 | -44.645.54 | | 归属于母公司所有者的净利润 | -17,671.95 | -51.476.83 | -44.645.87 | ...

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has been accepted for IPO on the Sci-Tech Innovation Board, marking it as the first company to be accepted under the reactivated fifth set of listing standards [3] Company Overview - Tainuo Maibo, established in 2015, focuses on innovative biopharmaceuticals for blood product replacement therapies targeting global markets [3] - The company has developed several candidate antibody drugs, including the globally first-in-class Staitouta monoclonal antibody injection, which has been approved for market [3] - Other candidates include TNM001 (anti-respiratory syncytial virus monoclonal antibody) in Phase III clinical trials, and TNM009 and TNM005 (anti-nerve growth factor and anti-varicella-zoster virus monoclonal antibodies) which have completed Phase I trials [3] Financial Performance - The company reported revenues of 4.34 million yuan in 2022, 0 yuan in 2023, and 1.51 million yuan in 2024, with a revenue of 16,930 yuan in Q1 2025 following the approval of Staitouta [4] - Net losses were reported at 429 million yuan in 2022, 446 million yuan in 2023, 515 million yuan in 2024, and 177 million yuan in Q1 2025 [4] Key Financial Metrics - As of March 31, 2025, total assets amounted to 1.13 billion yuan, with equity attributable to shareholders at 493 million yuan [5] - The company's debt-to-equity ratio was 56.48% as of Q1 2025, indicating a moderate level of financial leverage [5] - The basic and diluted earnings per share were both -0.48 yuan in Q1 2025, reflecting ongoing losses [5] Management and Ownership - The actual controllers, Huaxin Liao and Zheng Weihong, collectively hold 33.10% of the company's shares [5] - Huaxin Liao, the Chairman and CTO, has a background in biochemistry and extensive experience in molecular immunology [6] - Zheng Weihong, the Vice Chairman and General Manager, has a background in business management and experience in the pharmaceutical industry [7] Compensation - In 2024, Huaxin Liao received a salary of 2.63 million yuan, while Zheng Weihong earned 2.61 million yuan, both lower than the salary of the Chief Medical Officer, Wang Guomei, who earned 3.79 million yuan [8][9]

【导读】泰诺麦博IPO申请获受理，采用科创板第五套标准 7月31日晚，据上交所网站披露，珠海泰诺麦博制药股份有限公司（以下简称泰诺麦博）科创板上市申请获受理。泰诺麦博采用科创板第五套标准上市， 保荐机构是华泰证券。 科创板第五套标准重启 此次泰诺麦博的受理，可以说是真正迎来"新鲜血液"。招股书中，公司自述是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业，目前已 开发出"全球同类首创（First-in-Class）的斯泰度塔单抗注射液"。 7月1日，同样采用该套标准上市的禾元生物，成为首家重启后获上市委会议通过的企业，并在7月4日提交注册，7月18日注册生效。禾元生物之后，同样 采用科创板第五套标准的北芯生命，也很快提交注册并生效。 根据《上海证券交易所科创板股票上市规则》，科创板第五套标准为："预计市值不低于人民币40亿元，主要业务或产品需经国家有关部门批准，市场空 间大，目前已取得阶段性成果。医药行业企业需至少有一项核心产品获准开展二期临床试验，其他符合科创板定位的企业需具备明显的技术优势并满足相 应条件。"这是科创板五套上市标准中唯一对营业收入不做要求的。 记者注意到，从科创板2019年7月开 ...

Core Viewpoint - The IPO application of Zhuhai Tainomai Bo Pharmaceutical Co., Ltd. has been accepted, marking it as the first company to utilize the fifth set of standards for the Sci-Tech Innovation Board since its restart on June 18, 2025 [2][5]. Group 1: IPO Details - Tainomai Bo's IPO application was accepted on July 31, 2025, with Huatai Securities as the sponsor [2][3]. - The company plans to raise 1.5 billion RMB for new drug research and development, expansion of antibody production facilities, and to supplement working capital [12][13]. Group 2: Company Background - Tainomai Bo is an innovative biopharmaceutical company focused on global markets, specializing in blood product alternatives [8]. - The company has developed the "First-in-Class" Staitouta monoclonal antibody injection, recognized as a breakthrough treatment drug in the anti-infection field [9]. Group 3: Financial Performance - The company reported minimal revenue, with the Staitouta monoclonal antibody injection expected to generate sales starting in March 2025 [9]. - Tainomai Bo has incurred continuous net losses, with cumulative losses reaching 1.024 billion RMB by the end of the reporting period [11].

7月31日，上交所网站显示，该所受理了珠海泰诺麦博制药股份有限公司（以下简称"泰诺麦博"）的科创板IPO申请。 图片来源：上交所网站 招股说明书显示，泰诺麦博拟以第五套上市标准申报科创板，公司成为重启科创板第五套上市标准后首家受理的企业。同时，泰诺麦博获得资深专业机构 投资者投资。 泰诺麦博已开发多款抗体药物及候选抗体药物。其中，全球同类首创的斯泰度塔单抗注射液已获批上市，TNM001（抗呼吸道合胞病毒RSV单抗）正在进 行临床III期试验，2款候选药物TNM009（抗神经生长因子NGF单抗）及TNM005（抗水痘-带状疱疹病毒VZV单抗）已完成临床I期试验，1款候选药物 TNM006（抗人巨细胞病毒HCMV单抗）已获批IND，3款候选药物处于临床前阶段。 泰诺麦博表示，上述产品中，斯泰度塔单抗注射液、TNM005为全球同类首创（First-in-Class）或具有全球同类首创潜力，TNM001及TNM006等2款候选 药物具有国产首款潜力。 2022年至2024年，公司研发投入超过11亿元。本次IPO公司拟募资15亿元，募集资金规划用于新药研发项目、抗体生产基地扩建项目和补充营运资金项 目。 本次泰诺麦博获 ...

7月31日，上交所网站显示，该所受理了珠海泰诺麦博制药股份有限公司（以下简称"泰诺麦博"）的科创板IPO申请。 核心产品斯泰度塔单抗注射液获批上市 招股书显示，泰诺麦博成立于2015年，是一家创新生物制药企业。 泰诺麦博已开发多款抗体药物及候选抗体药物。其中，全球同类首创的斯泰度塔单抗注射液已获批上市，TNM001（抗呼吸道合胞病毒RSV单抗）正在进 行临床III期试验，2款候选药物TNM009（抗神经生长因子NGF单抗）及TNM005（抗水痘-带状疱疹病毒VZV单抗）已完成临床I期试验，1款候选药物 TNM006（抗人巨细胞病毒HCMV单抗）已获批IND，3款候选药物处于临床前阶段。 泰诺麦博表示，上述产品中，斯泰度塔单抗注射液、TNM005为全球同类首创（First-in-Class）或具有全球同类首创潜力，TNM001及TNM006等2款候选 药物具有国产首款潜力。 2022年至2024年，公司研发投入超过11亿元。本次IPO公司拟募资15亿元，募集资金规划用于新药研发项目、抗体生产基地扩建项目和补充营运资金项 目。 招股说明书显示，泰诺麦博拟以第五套上市标准申报科创板，公司成为重启科创板第五套上市标准 ...